购物车
您的购物车当前为空
Nic-15(compound 4n)是一种抗紧缩剂,旨在对抗胰腺肿瘤的低血管特性。由于这种特性,癌细胞能适应营养不足的肿瘤微环境并产生耐药性。该化合物通过调节PI3K/Akt/mTOR信号路径并缓解Gemcitabine引发的ER应激,有效抑制了MIA PaCa-2和PANC-1胰腺癌细胞的迁移和集落形成。同时,Nic-15与Gemcitabine联合应用,可以有效克服胰腺肿瘤的耐药问题,并在体内异种移植模型中显著增强Gemcitabine的疗效。

Nic-15(compound 4n)是一种抗紧缩剂,旨在对抗胰腺肿瘤的低血管特性。由于这种特性,癌细胞能适应营养不足的肿瘤微环境并产生耐药性。该化合物通过调节PI3K/Akt/mTOR信号路径并缓解Gemcitabine引发的ER应激,有效抑制了MIA PaCa-2和PANC-1胰腺癌细胞的迁移和集落形成。同时,Nic-15与Gemcitabine联合应用,可以有效克服胰腺肿瘤的耐药问题,并在体内异种移植模型中显著增强Gemcitabine的疗效。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 25 mg | ¥ 10,600 | 8-10周 | |
| 50 mg | ¥ 13,800 | 8-10周 | |
| 100 mg | ¥ 17,500 | 8-10周 |
| 产品描述 | Nic-15 (compound 4n) serves as an anti-constrictive agent targeting the low vascular characteristics of pancreatic tumors. These characteristics enable cancer cells to adapt to the nutrient-deficient tumor microenvironment and develop resistance to treatment. Nic-15 modulates the PI3K/Akt/mTOR pathway and alleviates ER stress induced by Gemcitabine. It significantly inhibits migration and colony formation in MIA PaCa-2 and PANC-1 pancreatic cancer cells. When used in combination with Gemcitabine, Nic-15 effectively addresses resistance issues in pancreatic tumors. In xenograft models in vivo, Nic-15 notably enhances the efficacy of Gemcitabine. |
| 分子量 | 412.47 |
| 分子式 | C25H26F2O3 |
| CAS No. | 2896739-91-4 |
| Smiles | C(=O)([C@H]1[C@@H](CC(CCC=C(C)C)=CC1)C2=C(F)C(F)=CC=C2)C3=C(O)C=CC=C3O |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
对于不同动物的给药剂量换算,您也可以参考 更多